Autologous haemopoietic stem cell transplantation (HSCT) represents a potential therapy for severe rheumatoid arthritis (RA). As a prelude to clinical trails, the safety and efficacy of haemopoietic stem cell (HSC) mobilisation required investigation as colony-stimulating factors (CSFs) have been reported to flare RA. A double-blind, randomised placebo-controlled dose escalation study was performed. Two cohorts of eight patients fulfilling strict eligibility criteria for severe active RA (age median 40 years, range 24-60 years; median disease duration 10.5 years, range 2-18 years) received filgrastim (r-Hu-methionyl granulocyte(G)-CSF) at 5 and 10 g/kg/day, randomised in a 5:3 ratio with placebo. Patients were unblinded on the fifth day of treatment and those randomised to filgrastim underwent cell harvesting (leukapheresis) daily until 2 ؋ 10 6 /kg CD34 ؉ cells (haemopoietic stem and progenitor cells) were obtained. Patients were assessed by clinical and laboratory parameters before, during and after filgrastim administration. RA flare was defined as an increase of 30% or more in two of the following parameters: tender joint count, swollen joint count or pain score. Efficacy was assessed by quantitation of CD34 ؉ cells and CFU-GM. One patient in the 5 g/kg/day group and two patients in the 10 g/kg/day group fulfilled criteria for RA flare, although this did not preclude successful stem cell collection. Median changes in swollen and tender joint counts were not supportive of filgrastim consistently causing exacerbation of disease, but administration of filgrastim at 10 g/kg/day was associated with rises in median C-reactive protein and median rheumatoid factor compared with placebo. Other adverse events were well recognised for filgrastim and included bone pain (80%) and increases in alkaline phosphatase (four-fold) and lactate dehydrogenase (two-fold). With respect to efficacy, filgrastim at 10 g/kg/day was more efficient with all patients (n = 5) achieving target CD34
Based on animal data and anecdotal case reports, haemopoietic stem cell transplantation (HSCT) has been proposed for the treatment of autoimmune diseases. [1] [2] [3] [4] [5] [6] [7] [8] [9] Recent advances, including the use of cytokine mobilised peripheral blood stem cells, have resulted in major reductions in the mortality and morbidity of autologous transplantation for malignant diseases 10, 11 and it now seems reasonable to consider HSCT as an experimental treatment for severe autoimmune diseases.
Rheumatoid arthritis (RA) is the most common systemic autoimmune disorder, affecting 1% of the population. RA incurs significant morbidity, with over 50% of individuals unable to work after 10 years of the disease, and has been estimated to shorten life by 5-10 years. Although various treatments may suppress disease activity, they require chronic administration, and do not cure the disease or prevent irreversible end organ damage. The associated economic costs are considerable, both to the individual and to the community. 12, 13 Patients with severe refractory RA may be ideal candidates for experimental HSCT as, unlike other systemic autoimmune diseases, vital organ function is usually uncompromised. In addition, RA is easily assessed by clinical and laboratory parameters. 7 As a preliminary to studies of high-dose therapy, the safety and efficacy of peripheral blood stem cell mobilisation in RA requires confirmation. Both granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) have been shown to flare arthritis in mice. 14, 15 Anecdotal clinical reports have reported exacerbation of autoimmune disease following treatment with G-CSF and GM-CSF. These have largely been in the context of Felty's syndrome [16] [17] [18] [19] [20] [21] or drug-induced neutropenia. 22, 23 Other reports have suggested that colony-stimulating factors may exacerbate vasculitis 19, 24, 25 and psoriasis 26 and precipitate bullous pyoderma gangrenosum 27 and neutrophilic dermatosis. 28 Potential causes for this effect may include leucocyte activation, 29 secondary release of proinflammatory cytokines 20 or possibly a direct effect on target tissues. However, there are many reports where CSFs have been used safely, for prolonged periods, to treat neutropenia in rheumatoid arthritis. 26, [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] In some cases, 43 it is unclear whether increased pain represents flare of disease or bone pain, which commonly accompanies CSF administration.
In addition, the quality of the stem cell product must be established. Abnormalities in the haemopoietic and immune systems in patients with RA 9, 44 have the potential to influence numbers and repopulating ability of haemopoietic progenitor cells and the composition and function of other cellular effectors in the harvested product. Patients with severe RA may have been exposed to myelosuppressive antirheumatic drugs, in some cases for many years, potentially influencing the mobilisation product and function of the graft. 44, 45 The primary objective of this study was to investigate the tolerability of granulocyte colony-stimulating factor (rHu-methionyl G-CSF, filgrastim; Amgen, Thousand Oaks, CA, USA) in patients with severe active, but stable, rheumatoid arthritis using doses suitable for progenitor cell mobilisation. The secondary objectives were to determine whether laboratory parameters of inflammation, principally C-reactive protein, were affected by filgrastim and to investigate the yield of PBSC as measured by CD34 ϩ and CFU-GM assays.
Patients and methods

Study design
This single centre study was approved by the Research Ethics Committee of St Vincent's Hospital and all patients gave informed consent. The design was a randomised, double blinded placebo-controlled phase I dose escalation study with two cohorts of eight patients, with five randomised to filgrastim and three receiving placebo in each cohort. The first cohort received filgrastim at 5 g/kg/day. After acceptable tolerability (defined as less than two patients in the filgrastim group compared with the placebo group experiencing an increase of 30% or greater from treatment baseline in two of swollen joint count, tender joint count, and pain score, or more than two patients achieving a white cell count of Ͼ75 ϫ 10 9 /l, or other intolerable events related to filgrastim) was confirmed for the first cohort, the dose was escalated to 10 g/kg/day for the second cohort. Patients received four daily doses of study drug or placebo in a double blind manner. On day 5, following assessment of clinical parameters, patients and assessors were unblinded and those receiving filgrastim underwent leukapheresis on a Cobe Spectra cell separator (Cobe, Lakewood, CO, USA) aiming to process 2.5 ϫ blood volume. Leukapheresis was continued for a maximum of 3 consecutive days until the target CD34 ϩ cell yield of 2 ϫ 10 6 /kg was achieved. Filgrastim was discontinued once the target yield was achieved or to a maximum of 6 days in total. Patients were reassessed at study completion on day 11, and also reviewed at a follow-up appointment 4-6 weeks following filgrastim administration.
Patient selection
Patients were enrolled 7-10 days before commencing filgrastim after satisfying the following eligibility criteria: age 18-65 years, a diagnosis of RA according to the criteria of the American College of Rheumatology (ACR) 46 for 2-20 years, failure of at least two second-line anti-rheumatic agents (ie anti-rheumatic drugs other than corticosteroids and non-steroidal anti-inflammatory drugs, NSAIDs). In addition, they fulfilled criteria for active disease, ie had six or more swollen joints, six or more tender joints, plus at least two of the following three criteria: (1) nine or more joints, capable of response, tender on pressure or motion; (2) 1 h or more of morning stiffness; (3) ESR of Ͼ28 mm/h. Patients had no other serious prior or intercurrent illness, including any major haematological disorder. Full blood count including differential and coagulation screen were within normal ranges or compatible with RA and/or its treatment (eg anaemia of chronic disorder, reactive neutrophilia and thrombocytosis, and lymphopenia due to corticosteroids were permitted). Biochemical screens showed plasma creatinine Ͻ0.15 mmol/l, liver enzymes Ͻ3 ϫ the upper limit of normal and plasma bilirubin Ͻ30 mmol/l. Premenopausal women had to have a negative pregnancy test, not be breast feeding and use contraceptive precautions. Informed consent was signed by all patients. Exclusion criteria included concurrent enrolment on any other protocol using an investigational drug or haemopoietic growth factor within 4 weeks of study entry, any disorder that compromised ability to give informed consent, known sensitivity to E. coli-derived drug preparations and previous entry to the study. Each patient was given an identification number in order of enrolment, with 1001 to 1008 for cohort 1 and 2001 to 2008 for cohort 2.
Concomitant anti-rheumatic medications
Patients were stabilised on corticosteroids and NSAIDs for at least 4 weeks prior to enrolment on the study and were continued at the same dose throughout the study. Minor fluctuations within the dose range of NSAIDs and paracetamol were permitted. Joint injections were not permitted within the 4-week 'run in' period or during the study. Additional paracetamol was permitted to manage sideeffects associated with filgrastim (such as bone pain). Patients on methotrexate, azathioprine, gold, hydroxychloroquine, sulphasalazine, d-penicillamine or cyclophosphamide had received the drug at the same dose for 3 months prior to beginning the study. Myelosuppressive drugs were stopped 1 week prior to the first dose of the study drug and recommenced 8 days later. Hence, patients were stable on anti-rheumatic medication prior to administration of filgrastim. A 2-week cessation of myelosuppressive anti-rheu-matic drugs, necessary to permit administration of filgrastim, was considered to be insufficient for their antirheumatic effect to be lost.
Assessment of safety
Prior to commencing treatment with the study drug, patients were assessed with baseline physical examination and measurement of swollen and tender joint counts (EULAR 28 joint count score), joint pain score on a 100 mm visual analogue scale (VAS), duration of morning stiffness (measured semi-quantitatively, 0 min, 0-30 min, 30-60 min, 1-2 h, 2-4 h, Ͼ4 h), adjectival patient and clinician global scales for disease (nil, mild, moderate, severe, very severe), vital signs, full blood count, plasma biochemistry, serum rheumatoid factor (RF), erythrocyte sedimentation rate (ESR), and C-reactive protein. All patients had a normal chest X-ray and ECG, with the exception of one patient in whom the ECG suggested ischaemic heart disease which had been excluded by cardiac angiography. Pre-treatment bone marrow aspirates in 14 out of 16 patients agreeing to the procedure confirmed normal appearances or appearances consistent with RA and/or its treatment in all patients.
During the study, patients were assessed with daily full blood count on days 1-5 and on days 6 and 7 where leukapheresis was performed. Plasma biochemistry, C-reactive protein, ESR and RF were repeated on the day after the final administration of the study drug. Patients completed a daily diary detailing pain score, morning stiffness, adjectival patient global scale and specific symptoms. Vital signs were recorded when patients attended clinic. On day 5, double-blind measurement of swollen joint count, tender joint count and adjectival clinician global scale were performed, after which patient and assessor were unblinded.
The study was terminated at day 11 when all baseline assessments were repeated. Four to 6 weeks following study drug administration, a follow-up interview was conducted with repeat joint counts and blood tests. More than 95% of joint counts were performed by one assessor (AF), the remainder by a second assessor. Assessment before and after the blinded period was performed by the same assessor on all occasions.
Assessment of efficacy
CD34
ϩ cell counts were assessed by flow cytometry as previously described. 47 CFU-GM count was performed on thawed cells which had been frozen in 10% dimethyl sulphoxide using 14-day culture in methylcellulose media (Methocult GF H4434; Stem Cell Technologies, Vancouver, Canada) as previously described. 48 
Analysis of data
Descriptive statistical methods (medians, ranges) were used to compare both filgrastim cohorts with the combined placebo group and to look for a dose escalation effect between the 5 and 10 g/kg/day cohorts. To detect a flare in the RA of individual patients, we defined a flare as an increase from baseline of 30% or more of two of the following parameters; tender joint count, swollen joint count or pain score on VAS.
Results
Patient demographics
Patient data are summarised in Table 1 . All patients were Caucasian. One patient out of 10 randomised to filgrastim required central venous access for leukapheresis in view of poor peripheral venous access.
Safety data
Descriptive data for changes in rheumatological variables are summarised in Tables Table 4 ). The increased disease activity was also reflected by worsening in the semi-quantitative parameters shown in Table 3 .
Median values of swollen and tender joint counts and semi-quantitative assessment of morning stiffness and patient and clinician global assessments remained largely stable and were not supportive of filgrastim consistently causing exacerbation of disease (Tables 2, 3 and 4) . Administration of filgrastim at 10 g/kg/day was associated with a rise in median C-reactive protein level which corrected by day 11 and a progressive rise in rheumatoid factor at days 5 to 11 (Table 5 ). It is difficult to comment on changes in ESR as there was a progressive rise in the placebo group.
The median joint pain scores (by VAS) support a dosedependent increase in pain during the blinded phase of the study, which improved after cessation of the filgrastim (Table 2) . Here there may be some overlap with filgrastim induced bone pain, the most common adverse event occurring in 8/10 filgrastim vs 0/6 placebo patients. Other adverse events were routine for filgrastim and included headache (5/10 filgrastim vs 2/6 placebo patients) and fatigue/tiredness (5/10 filgrastim vs 2/6 placebo patients).
There was an increase in median alkaline phosphatase from baseline on day 5 (3.5-3.9 ϫ placebo) returning to 1.3-1.4 ϫ placebo by day 11. Similarly, median LDH increased on day 5 (1.8-1.9 ϫ placebo) and settled to 1.1-1.2 ϫ placebo by day 11. The absence of significant change in disease activity of the placebo patients provided support that withdrawal of anti-rheumatic drugs for the short study period did not in itself exacerbate their RA.
Efficacy data
Filgrastim administration produced a significant rise in WCC (and neutrophil count) in both treatment groups, with a median peak of 42. /l) at day 3 in the 10 g/kg/day Table 3 Summary of changes in morning stiffness, clinician global and patient global (assessed semi-quantitatively) Table 6 . Filgrastim at a dose of 10 g/kg/day was more efficient in terms of mobilisation in that target CD34 ϩ yields were achieved with one leukapheresis and total CFU-GM counts from this group were higher.
Discussion
This placebo controlled study is the first to investigate the safety and efficacy of filgrastim in patients with severe active RA for stem cell collection. In a minority of patients, filgrastim administration was associated with an early or late transient flare of RA, but this did not prevent successful harvesting. In only one patient was the flare significant enough to warrant an increase in the steroid dosage. Progenitor cell yields were satisfactory in all patients based on both CD34 ϩ counts and CFU-GM assays, and fulfilled recently published criteria in the EBMT/EULAR consensus guidelines for autoimmune disease (ie CD34 ϩ count Ͼ2 ϫ 10 6 /kg and CFU-GM Ͼ2 ϫ 10 4 /kg). 6 In all patients receiving filgrastim at 10 g/kg/day, the target threshold of 2 ϫ 10 6 /kg CD34 ϩ cells was achieved with one leukapheresis.
One other pilot study has recently addressed the safety of administering filgrastim to patients with RA. 49 Five patients were given intramuscular or intra-articular methylprednisolone (median 80 mg, range 40-120 mg) prior to administration of filgrastim at 5 g/kg/day to protect against flare.
Disease activity remained stable although the pre-administration of corticosteroids may have inhibited any proinflammatory effect of filgrastim. The patients did not undergo leukapheresis, but efficacy, quantitated indirectly using peripheral blood CD34 ϩ count, was considered adequate.
Our study differs in that it has shown that RA flare may be a complication of filgrastim administration for stem cell mobilisation. However, routine pre-administration of corticosteroids is unnecessary in the majority of patients. Use of anti-inflammatory agents (which in our study were kept stable for 1 month prior to and during the study period) could be individualised to minimise flare. Alternatively, the risks of flare could be discussed with the patient, who could then decide whether or not to receive intra-articular or intramuscular steroid injections.
Our results also show that the target thresholds can be achieved in one leukapheresis without the use of cytotoxic agents, such as cyclophosphamide, for priming. Although cyclophosphamide priming may increase the yield of PBSC, it has the potential to add morbidity and even mortality. 11, 50 In addition, a recent analysis suggests that the use of cyclophosphamide priming may contribute to an excess incidence of secondary myelodysplasia observed with peripheral blood stem cells compared with bone marrow in autologous transplantation. 51 The above study is reassuring in that sufficient HSC may be mobilised from most patients with RA with filgrastim alone. Avoidance of additional cytotoxic agents in mobilisation may be desirable in RA patients who even without the risks of autologous transplantation are known to have a higher incidence of leukaemia from the disease and conventional treatments. 52 Further studies are necessary on stem cell mobilisation in patients with RA before large scale clinical trials of autologous HSCT can commence. Analysis of greater numbers of patients will define the risk of flare more accurately. Mobilised stem cells should be evaluated in short-and long-term in vitro culture to reassure that such harvests are able to reconstitute long-term haemopoiesis. The composition of the harvest should be determined and the functional properties of contaminating lymphocytes and other cellular effectors should be investigated. Such information may be valuable in planning graft manipulation strategies although at present it is unknown whether such processing will be clinically advantageous. Further investigation will naturally depend on the success of autografting in RA patients, although early results of unmanipulated autografting in sporadic cases 53, 54 and in our own clinical trial 55 appear promising.
